ClinicalTrials.gg

Program

bulumtatug fuvedotin

Also written as “9MW2821”, “CVL006 in combination with 9MW2821” and “9MW2821+other anticancer therapy”.

Its studies are mostly in Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms, led by 2 companies.

Furthest: phase 3, since Dec 12, 202313 company-led studies, 13 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscience1212 open or runningphase 3since Dec 12, 2023Jan 19, 2022Dec 31, 2026phase 2 · NCT06079112
Convalife (Shanghai)11 open or runningphase 2since May 6, 2026May 6, 2026Apr 30, 2029phase 2 · NCT07615660

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2022First study: phase 2 study in Solid TumorsNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT05216965 · 208 planned · China
  2. Feb 22, 2023Phase 1 study in Advanced Malignant Solid TumorsMabwell (Shanghai) Bioscience · NCT05773937 · 40 planned · China
  3. Sep 25, 2023Phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112 · 100 planned · China
  4. Dec 12, 2023Phase 3 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06196736 · 432 planned · China
  5. Jul 1, 2024Phase 2 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06492005 · 160 planned · China
  6. Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326 · 460 planned · China
  7. Nov 14, 2024Phase 3 study in Uterine Cervical NeoplasmsMabwell (Shanghai) Bioscience · NCT06692166 · 420 planned · China
  8. Mar 20, 2025Phase 1 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06908928 · 52 planned · United States
  9. Apr 8, 20252 phase 2 studiesMabwell (Shanghai) Bioscience · NCT06926998, NCT06947226
  10. Dec 18, 2025Phase 2 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT07314723 · 90 planned · China
  11. Apr 22, 2026Phase 3 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT07556848 · 356 planned · China
  12. May 6, 2026Convalife (Shanghai)’s first study: phase 2 study in Advanced Solid TumorNew to Convalife (Shanghai)Convalife (Shanghai) · NCT07615660 · 108 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112
  2. May 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06908928
  3. May 1, 2027Primary completion: phase 2 study in Gynecological MalignanciesMabwell (Shanghai) Bioscience · NCT06926998
  4. Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326

TargetBeta

NECTIN4 →read by rule
“An antibody drug conjugate (ADC) composed of bulumtatug, a humanized monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07615660Advanced Solid Tumor2Not yet recruitingConvalife (Shanghai)Apr 30, 2029108
NCT07556848Triple Negative Breast Neoplasms · China3Not yet recruitingMabwell (Shanghai) BioscienceDec 2027356
NCT07314723Carcinoma, Transitional Cell · China2RecruitingMabwell (Shanghai) BioscienceDec 31, 202790
NCT06947226Solid Tumors · China2Not yet recruitingMabwell (Shanghai) BioscienceApr 2026188
NCT06926998Gynecological Malignancies · China2Not yet recruitingMabwell (Shanghai) BioscienceMay 1, 2027260
NCT06908928Triple Negative Breast Neoplasms · United States1RecruitingMabwell (Shanghai) BioscienceMay 202752
NCT06692166Uterine Cervical Neoplasms · China3RecruitingMabwell (Shanghai) BioscienceDec 9, 2027420
NCT06592326Carcinoma, Transitional Cell · China3RecruitingMabwell (Shanghai) BioscienceSep 2027460
NCT06492005Triple Negative Breast Neoplasms · China2RecruitingMabwell (Shanghai) BioscienceJul 2026160
NCT06196736Advanced Urothelial Carcinoma · China3RecruitingMabwell (Shanghai) BioscienceSep 2026432
NCT06079112Advanced Urothelial Carcinoma · China2RecruitingMabwell (Shanghai) BioscienceDec 31, 2026100
NCT05773937Advanced Malignant Solid Tumors · China1RecruitingMabwell (Shanghai) BioscienceDec 31, 202440
NCT05216965Solid Tumors · China2RecruitingMabwell (Shanghai) BioscienceDec 2025208

How it is read

Names in the registry

  • “9MW2821”, 10 entries
  • “bulumtatug fuvedotin”, 2 entries
  • “CVL006 in combination with 9MW2821”, 2 entries
  • “9MW2821+other anticancer therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.